Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

Completed · Phase 2

Conditions studied: Idiopathic Subglottic Stenosis

In brief

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Key facts

Study ID

NCT05309616

Run by

Yale University

People needed

10

Starts

2025-02-20

Expected to finish

2026-05-19

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• diagnosis of idiopathic subglottic stenosis

You may not qualify if…

• History of active or latent tuberculosis infection
• History of inflammatory bowel disease
• Pregnancy or lactation
• Known allergic reactions to study drug
• Disease involving the vocal cords
• Individuals who are taking drugs known to trigger angioedema, including use acquired angioedema from drugs such as ACE inhibitors (e.g. Lisinopril) and nonsteroidal anti-inflammatory drugs (NSAIDs) and individuals with a history of other forms of angioedema such as hereditary and Clesterase deficiency

Where it is running

• Yale New Haven Hospital — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.